WHO ICTRP trial
Research on safety and effect of lipid improvement of rosuvastatin combined with…
JPRN-UMIN000000935 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-UMIN000000935 |
|---|---|
| Public title | Research on safety and effect of lipid improvement of rosuvastatin combined with fenofibrate or EPA in type 2 diabetic patients with hyperlipidemia. |
| Scientific title | Research on safety and effect of lipid improvement of rosuvastatin combined with fenofibrate or EPA in type 2 diabetic patients with hyperlipidemia. - Research on safety and effect of lipid improvement of rosuvastatin combined with fenofibrate or EPA in type 2 diabetic patients with hyperlipidemia. |
| Primary sponsor | Hiroshima University Hospital Department of Endoclinology |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | Japan |
| Conditions | type 2 diabetic patients with hyperlipidemia |
| Interventions | Following a 8 weeks medication with rosuvastatin 2.5mg, subjects with not achieved NCEP ATPIII goal will be receive treatment with fenofibrate 200-201mg for 24 weeks. Following a 8 weeks medication with rosuvastatin 2.5mg, subjects with not… |
| Registration date | Jan 9, 2008 |
| Target size | 200 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: